Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

Synthetix Inc. DBA Helix Chemical Supply

Has Helix Chemical Supply received an FDA warning letter? Yes. FDA issued a warning letter dated February 7, 2024 concerning products containing semaglutide and tirzepatide.

Letter facts

Letter date
February 7, 2024 (2024-02-07)
Issuing office
Center for Drug Evaluation and Research | CDER
Products named
SemaglutideTirzepatide
Violation categories
Unapproved new drugMisbranding

Understanding these violation categories

Unapproved new drug

FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

Factual Violation Summary

FDA says the website sold Semaglutide and Tirzepatide as unapproved new drugs without FDA-approved applications, and as misbranded drugs lacking adequate directions for use despite 'research use only' claims.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • Unapproved new drugs
  • Misbranded drugs

More letters about Semaglutide

Recent FDA warning letters concerning Semaglutide:

Similar violations (Unapproved new drug)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.